Live Breaking News & Updates on Princeton University Office Of Technology Licensing

Stay updated with breaking news from Princeton university office of technology licensing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CCM Biosciences Announces Launch of 5Prime Sciences Business Unit

CCM Biosciences Announces Launch of 5Prime Sciences Business Unit
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Nucleic Acids Research , Princeton University , Raj Chakrabarti At Princeton University , Princeton University Office Of Technology Licensing , American Chemical Society , Nature Publishing Group , Chakrabarti Advanced Technology , Biosciences Inc , Quest Diagnostics , Toyobo Life Sciences , Group Inc , Molecular Diagnostics , Polymerase Chain Reaction , Next Generation Sequencing , Raj Chakrabarti , Princeton University Office , Technology Licensing , Celera Diagnostics , New England Biolabs , Toyobo Life ,

CCM Biosciences Announces Launch of 5Prime Sciences Business Unit – IT Business Net

CCM Biosciences Announces Launch of 5Prime Sciences Business Unit – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United States , Group Inc , Princeton University , Nature Publishing Group , Quest Diagnostics , Nucleic Acids Research , Raj Chakrabarti At Princeton University , Toyobo Life Sciences , Chakrabarti Advanced Technology , Biosciences Inc , Princeton University Office Of Technology Licensing , American Chemical Society , Molecular Diagnostics , Polymerase Chain Reaction , Next Generation Sequencing , Raj Chakrabarti , Princeton University Office , Technology Licensing , Celera Diagnostics , New England Biolabs , Toyobo Life ,

Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results

Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results
News provided by
Share this article
Share this article
NEWARK, N.J., March 17, 2021 /PRNewswire/ Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three months ended January 31, 2021.
Q2 FY 2021 Consolidated Financial and Operational Highlights
Revenue of $1.0 million, generated by Rafael Holdings real estate portfolio, decreased from $1.2 million in the year-ago quarter due, in part, to the sale of its building in Piscataway, NJ.
Loss per share of $0.50 compared to a loss per share of $0.08 in the year ago quarter primarily due to a $7.0 million impairment of the company s interest in Altira, as described below. ....

United States , Howard Jonas , Fordoz Pharma , Joshua Rabinowitz , Third Party , Sarcoma Alliance For Research , Lipomedix Pharmaceuticals Ltd , Rafael Pharmaceuticals , Princeton University Office Of Technology Licensing , Rafael Holdings Inc , Barer Institute , Rafael Pharmaceuticals Inc , Investment In Rafael Pharmaceuticals , Rp Finance , Rafael Holdings , Drug Administration , Rafael Holding , Department Of Chemistry , Company Class , Other Pharmaceuticals , Rafael Holding Board Of Directors , Holding Board , Ameet Mallik , Chief Executive Office , Rafael Holding Chief Commercial , Rafael Pharmaceutical ,

Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor Program

Barer Institute Announces Licensing Agreement with Princeton University s Office of Technology Licensing for SHMT Inhibitor Program
News provided by
Share this article
Share this article
NEWARK, N.J., Dec. 22, 2020 /PRNewswire/ The Barer Institute, a cancer drug development initiative of Rafael Holdings, Inc., (NYSE: RFL), today announced that it has reached an agreement with Princeton University s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program and related intellectual property.
SHMT is critical source of 1–carbon units utilized in cellular nucleotide synthesis. SHMT isoforms are upregulated in numerous cancers and have been shown to be a valuable target for metabolic cancer treatment. ....

Israel General , New Jersey , United States , Princeton University , Ted Taylor , Joshua Rabinowitz , Lipomedix Pharmaceuticals Ltd , Princeton University Office Of Technology Licensing , Rafael Holdings Inc , Barer Institute , Rafael Pharmaceuticals Inc , Department Of Chemistry , Rabinowitz Lab , Princeton Chemistry Department , Rafael Holdings , Technology Licensing , Professor Joshua Rabinowitz , Chemistry Department , Ari Landon , Professor Rabinowitz , Rafael Pharmaceuticals , Lipomedix Pharmaceuticals , இஸ்ரேல் ஜநரல் , புதியது ஜெர்சி , ஒன்றுபட்டது மாநிலங்களில் , ப்ரிந்ஸ்டந் பல்கலைக்கழகம் ,